作者:Akihito Fujii、Yoshito Fujima、Hiroshi Harada、Masaya Ikunaka、Toru Inoue、Shiro Kato、Keisuke Matsuyama
DOI:10.1016/s0957-4166(02)00004-6
日期:2001.12
(+/-)-3-(2-Aminopropyl)-7-benzyloxyindole 1. assembled from 7-benzyloxyindole 3 in 59% overall yield, is resolved with O.O'-di-p-toluoyl L-(2R,3R)-tartaric acid 7 into (R)-1. a key intermediate of AJ-9677 2 (selective adrenaline beta(3)-agonist) in 99.5% e.e. and 36% overall yield. The unwanted enantiomer (S)-1 (61.9% e.e.: recovered in 57% yield from the crystallization filtrate) can be reused in another round of resolution after its enantiomeric purity is lowered to 3.7% by Raney Co treatment under a hydrogen atmosphere. (C) 2002 Elsevier Science Ltd. All rights reserved.
(±)-3-(2-氨基丙基)-7-苄氧基吲哚 1 可通过由 7-苄氧基吲哚 3 组装而成,总收率 59%。7- 苄氧基吲哚 3 可用 O.O'- 对甲苯酰-L-(2R,3R)-酒石酸 7 分析成(R)-1,其为 AJ-96772(一种选择性肾上腺素 β(3)-激动剂)的重要中间体,对映体纯度达 99.5%,总收率 36%。通过氢气氛下用 Raney 钴处理,可将未见的对映体(S)-1(61.9% 的对映体纯度:以 57% 的收率从 结晶滤液中回收)用于另一轮解析前,需将其对映体纯度降低至 3.7%。AJ-96772 通过培养至出现晶体析出,随后过滤收集晶体,以确保最终产物的光学纯度。本研究结果可作为相关药物研发的参考。© 2002 Elsevier Science Ltd. 所有权利保留。